Lung Cancer Considered

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study.

Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School

Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair

In this episode of Lung Cancer Consider, host Dr. Stephen Liu previews the upcoming IASLC 2024 Asia Conference on Lung Cancer with meeting co-chair, Dr. Feng-Ming (Spring) Kong.

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.

In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Isabella Favato Barcelos and Dr. William Nassib William.

Guests:

Dr. Clarissa Mathias

Medical Oncologist at Oncoclinicas Bahia and Hospital Santa Izabel

Dr. Isabella Favato Barcelos

Medical Oncologist, Oncoclinicas&Co/MedSir, Brazil

Dr. William Nassib William

National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conference on Lung Cancer as nurse practitioners.

Hear their favorite sessions, their observations as first-time attendees, and why they hope to see more nurse practitioners at future IASLC events.

Guests:

Jillian Thompson, MSN, ANP-BC, AOCNP

Nurse Practitioner

MedStar Georgetown University Hospital

Lombardi Comprehensive Cancer Center

Stephanie McDonald RN, MSN, FNP-BC, AOCNP

Nurse Practitioner

Dana-Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.

In this episode, host Dr. Coral Olazagasti moderates a discussion in Spanish about highlights from the conference with Dr. Maria Velez and Dr. Rossana Ruiz.

Guests:

Dr. Coral Olazagasti

Assistant Professor at the Sylvester Cancer Center, University of Miami at Miami, Florida.

Dr. Rossana Ruiz

Medical Oncologist from Universidad Peruana Cayetano Heredia Global Health Fellowship at MGH in Boston, Massachusetts

Thoracic Medical Oncologist, Instituto Nacional de Enfermedades Neoplasicas and AUNA-Oncosalud in Lima, Peru

Dr. Maria Velez

Clinical Instructor, Division of Hematology-Oncology

UCLA David Geffen School of Medicine in Los Angeles, California

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research.

Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain.

Guests:

Dr. Hidehito Horinouchi

Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo

General Secretary, Japan Clinical Oncology Group

Dr. Noemi Reguart

Clinical Professor at the University of Barcelona

Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain

WCLC 2025 Co-Chair

Dr. Jacob Sands

Assistant Professor of Medicine, Harvard Medical School

Lowe Cancer Center for Thoracic Oncology

Dana Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.

In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang and Dr. Lin Wu.

Guests:

Dr. Chunxia Su

Professor of Oncology at Tongji University

Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital

Dr. Huijuan Wang

Professor of Oncology Department of Medical Oncology

The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

Dr. Lin Wu

Director, Thoracic Oncology Department II

Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference.

Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC.

Guests:

Dr. Fiona Hegi-Johnson

Radiation Oncologist at the Peter MacCallum Cancer Centre

Senior Research Fellow at the University of Melbourne

Dr. Xiuning Le, M.D., Ph.D.

Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology

University of Texas M.D. Anderson Cancer Center

Dr. Gerrina Ruiter, M.D., Ph.D.

Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer Institute

Amsterdam, The Netherlands

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.

In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Jii Bum (Joy) Lee.

Guests:

Dr. Chul Kim, MD

Associate Professor at Georgetown University with a focus on thoracic oncology

Dr. Jeongmin Seo, MD

Clinical Assistant Professor at Seoul National University Bundang Hospital with a focus on thoracic oncology

Dr. Jii Bum (Joy) Lee, MD, PhD

Yonsei Cancer Center, Yonsei University College of Medicine

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference.

Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018.

Guests:

Dr. Tina Cascone

Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology

University of Texas MD Anderson Cancer Center in Houston, Texas

Dr. Marina Chiara Garassino

Director, Thoracic Oncology Program and Professor of Medicine

University of Chicago

Dr. Matthew Smeltzer

Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health

University of Memphis

Professor Caicun Zhou

Chief Physician and Director of the Department of Medical Oncology

Tongji University in Shanghai Pulmonary Hospital